Global Liposomal Doxorubicin Market Size & Outlook

The global liposomal doxorubicin market size was estimated at USD 1,310.1 million in 2024 and is projected to reach USD 2,378.7 million by 2033, growing at a CAGR of 7% from 2025 to 2033.
Revenue, 2024 (US$M)
$1,310.1
Forecast, 2033 (US$M)
$2,378.7
CAGR, 2025 - 2033
7%
Report Coverage
Worldwide

Global liposomal doxorubicin market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Global liposomal doxorubicin market highlights

  • The global liposomal doxorubicin market generated a revenue of USD 1,310.1 million in 2024 and is expected to reach USD 2,378.7 million by 2033.
  • The market is expected to grow at a CAGR (2025 - 2033) of 7% by 2033.
  • In terms of segment, lipodox accounted for a revenue of USD 546.8 million in 2024.
  • Lipodox is the most lucrative product segment registering the fastest growth during the forecast period.
  • In terms of region, North America was the largest revenue generating market in 2024.
  • Country-wise, India is expected to register the highest CAGR from 2025 to 2033.

Global data book summary

Market revenue in 2024USD 1,310.1 million
Market revenue in 2033USD 2,378.7 million
Growth rate7% (CAGR from 2025 to 2033)
Largest segmentLipodox
Fastest growing segmentLipodox
Historical data covered2021 - 2023
Base year for estimation2024
Forecast period covered2025 - 2033
Quantitative unitsRevenue in USD million
Market segmentationDoxil/Caelyx, Lipodox, Myocet

Other key industry trends

  • In terms of revenue, the North America accounted for 37.6% of the global liposomal doxorubicin market in 2024.
  • By country, the U.S. is projected to lead the global market in terms of revenue in 2033.
  • By country, India is the fastest growing regional market and is projected to reach USD 85.7 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Liposomal Doxorubicin Market Companies

Name Profile # Employees HQ Website
SRS Life Sciences View profile 51-100 Singapore, Central Region, Singapore, Asia https://www.srslife.com
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical View profile 501-1000 Shanghai, Shanghai, China, Asia http://www.fd-zj.com/desktopmodules/ht/English/home/Index.aspx
Cipla View profile 10001+ Mumbai, Maharashtra, India, Asia http://www.cipla.com
Cadila Pharmaceuticals View profile 5001-10000 Ahmedabad, Gujarat, India, Asia http://cadilapharma.com
Sun Pharmaceutical Industries View profile 10001+ Mumbai, Maharashtra, India, Asia http://www.sunpharma.com
Lupin View profile 10001+ Mumbai, Maharashtra, India, Asia https://www.lupin.com
GSK PLC View profile 70200 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS https://www.gsk.com
Merck & Co Inc View profile 72000 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 https://www.merck.com
Sanofi SA View profile 87994 46, avenue de la Grande Armée, Paris, France, 75017 https://www.sanofi.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com
Johnson & Johnson View profile 134400 One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 https://www.jnj.com

Global liposomal doxorubicin market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liposomal doxorubicin market will help companies and investors design strategic landscapes.


Lipodox was the largest segment with a revenue share of 41.74% in 2024. Horizon Databook has segmented the Global liposomal doxorubicin market based on doxil/caelyx, lipodox, myocet covering the revenue growth of each sub-segment from 2021 to 2033.


  • Global Liposomal Doxorubicin Product Outlook (Revenue, USD Million, 2021-2033)
    • Doxil/Caelyx
    • Lipodox
    • Myocet
    • Others
  • Global Liposomal Doxorubicin Application Outlook (Revenue, USD Million, 2021-2033)
    • Breast Cancer
    • Ovarian Cancer
    • AIDS-related Kaposi's Sarcoma
    • Multiple Myeloma
    • Other Solid Tumors
  • Global Liposomal Doxorubicin Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Reasons to subscribe to Global liposomal doxorubicin market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Global liposomal doxorubicin market databook

  • Our clientele includes a mix of liposomal doxorubicin market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of global-level data and insights on the Global liposomal doxorubicin market , including forecasts for subscribers. This global databook contains high-level insights into Global liposomal doxorubicin market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Global liposomal doxorubicin market size, by regions, 2021-2033 (US$M)

Top 10 countries: Liposomal doxorubicin market size, 2024 (US$M)

Global liposomal doxorubicin market share, by product, 2024 & 2033 (%, US$M)

Liposomal doxorubicin market: Opportunity assessment by country

Global liposomal doxorubicin market, by region, 2024 (US$M)

Global liposomal doxorubicin market size, by regions, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online